


Figure 2. Effects of downregulation of SBP1 on cell proliferation, apoptosis, and GPX1 activity. A, cell proliferation was detected by CCK-8 assay. When both SBP1-siRNA and the control group were cultured under normal conditions, the proliferation rate of the control group was higher than that of the SBP1-siRNA group ($P < 0.05$). However, when both groups were treated with 100 $\mu\text{mol/L}$ hydrogen peroxide, the cell proliferation in the control group was significantly suppressed after 48 hours whereas the SBP1-siRNA group maintained most of its proliferative ability ($P < 0.0001$). B, cell apoptosis was analyzed by flow cytometry. Fluorescein isothiocyanate (FITC)-labeled Annexin V and fluorescent dye propidium iodide (PI) were used to stain cells. No obvious differences were shown between the SBP1-siRNA group and the control group when cultured using normal medium. A significant decrease in the apoptosis rate of the SBP1-siRNA group was observed when cells were treated with hydrogen peroxide (300 $\mu\text{mol/L}$) for 12 hours. C, Western blot analysis showed the different HIF-1 α and GPX1 expression levels in SMMC7721 cells following SBP1-siRNA transfection and different hydrogen peroxide treatment. GAPDH was used as a loading control. D, GPX1 activity of the SBP1-siRNA group was significantly higher than that of the control groups ($P < 0.001$), and a slight increase could be observed between the hydrogen peroxide-treated and -untreated groups. All experiments were repeated at least 3 times.

and the newly formed structure were colocalized, indicating that the 2 proteins might bind to each other under oxidative stress (Fig. 3B). After silencing SBP1, no specific association between SBP1 and GPX1 could be observed, but the GPX1 nuclear bodies remained (Fig. 4). The physiologic and pathologic implications behind this phenomenon would be discussed later.

Decreased SBP1 and increased GPX1 activity correlate with vascular invasion in HCC patients

We further validated our *in vitro* findings using clinical samples obtained from patients with HCC (Fig. 5A, Fig. 5B). We observed that samples with low expression of SBP1 had relatively high GPX1 activities whereas samples with high expression of SBP1 had limited GPX1 activities. Overall, the

Figure 3. Immunofluorescence images of SBP1 and GPX1 in SMMC7721-Mock cells. **A**, SMMC7721 cells were stained with anti-SBP1 monoclonal antibody (red) and anti-GPX1 polyclonal antibody (green). **a-h**, cells were cultured without hydrogen peroxide treatment, and GPX1 localized exclusively in the cytoplasm (**b**, **f**) whereas SBP1 could be found both in the cytoplasm and the nucleus (**c**, **g**). **i-p**, cells were treated with hydrogen peroxide (50 μ mol/L) for 12 hours before fixation. Images showed that both GPX1 and SBP1 had established specific nuclear bodies (**j**, **k**, **n**, **o**), and most of the GPX1 nuclear bodies were colocalized with SBP1 bodies (**l**, **p**). **B**, two high magnification images are presented here to show the details of the colocalization of SBP1 and GPX1 nuclear bodies. Some had already merged together (indicated by arrowheads) whereas others were still in the process of colocalization (indicated by arrows). We carried out the experiment at least 3 times and obtained similar results.



vascular invasion group had a lower SBP1 expression and relatively higher GPX1 activity, particularly in patients with HCC with macrovascular invasion, compared with those of the nonvascular invasion group (Supplementary Table S1).

Immunohistochemical characteristics

Representative photomicrographs of tumor tissues showing the various staining patterns are presented in Fig. 6A. In tumor tissues, we observed 26.01% (84 of 323) with scores of 0, 38.08% (123 of 323) with scores of +, 22.60% (73 of

323) with scores of ++, and 13.31% (43 of 323) with scores of +++. Of the 84 patients with scores of 0 in the tumor tissues, 78.57% (66 of 84) experienced recurrent disease, as did 65.86% (81 of 123), 52.05% (38 of 73) and 53.49% (23 of 43) of patients with scores of +, ++, and +++, respectively. With Kaplan-Meier estimates and log-rank tests considering the intensities of staining in tumor tissues, we found that the cutoff score of ++ was suitable to be the criterion (Supplementary Fig. S1); thus, we defined the samples with scores of 0 and + as negative and the samples with ++ and +++ as positive. According to the criterion




Figure 4. Images of SBP1 and GPX1 in SMMC7721-siRNA-SBP1 cells. SMMC7721-siRNA-SBP1 cells were stained with anti-SBP1 monoclonal antibody (red) and anti-GPX1 polyclonal antibody (green). a-h, cells were cultured under normal conditions. i-p, cells were treated with hydrogen peroxide (50 $\mu\text{mol/L}$) for 12 hours before fixation. SBP1 expression was downregulated to a minimal level by siRNA treatment (c, g, k, o) whereas GPX1 expression was unaffected (b, f, j, n). Similarly, GPX1 nuclear bodies were formed under hydrogen peroxide treatment (j, n) but were not colocalized with SBP1 bodies (l, p). We carried out the experiments at least 3 times and obtained similar results.

used, 64.09% (207 of 323) of the patients with HCC were negative for expression of SBP1.

As showed in Supplementary Table S2, negative SBP1 expression in tumor tissues was significantly correlated with patient age ($P = 0.045$), α -fetoprotein ($P < 0.001$), tumor size ($P = 0.005$), tumor number ($P = 0.019$), tumor encapsulation ($P = 0.034$), vascular invasion ($P < 0.001$), and recurrence ($P < 0.001$). Levels of SBP1 expression in tumor tissues were significantly different among patient groups according to the degree of vascular invasion ($P < 0.001$).

SBP1 expression in tumor tissue and prognosis


In the univariate analysis, patient sex, serum albumin (ALB), tumor differentiation, tumor encapsulation, tumor size, tumor number, and vascular invasion were associated with OS; patient sex, serum alanine transaminase (ALT), tumor encapsulation, tumor size, and vascular invasion were associated with cumulative recurrence (Supplementary Table S3). In the multivariate analysis, patient sex, serum ALB, tumor differentiation, tumor encapsulation, tumor size, and vascular invasion were associated with OS; patient

sex, serum ALT, tumor encapsulation, tumor size, and vascular invasion were associated with cumulative recurrence (Supplementary Table S4). Univariate and multivariate analyses showed that SBP1 expression in tumor cells was an independent risk factor for both OS ($P < 0.001$) and recurrence ($P < 0.001$).

On the basis of Kaplan-Meier survival curves, patients who were negative for expression of SBP1 in tumor tissues experienced shorter OS periods ($P < 0.001$) and higher recurrence rates ($P < 0.001$; Fig. 6B). We investigated the predictive value of SBP1 in HCC. Of the patients with negative SBP1 expression in their tumor tissues, 69.08% (143 of 207) had recurred, and 114 patients of these patients experienced recurrence within 2 years. In patients with positive SBP1 expression in tumor cells, the recurrence rate was only 50.86% (59 of 116), and 28.45% (33 of 116) of these patients experienced recurrence within 2 years. Kaplan-Meier survival curves revealed that SBP1 was a significant prognostic factor for OS and early recurrence in HCC.

We further stratified patients by Milan criteria and investigated the predictive value of SBP1 in different

Figure 5. Relationships among clinical tumor characteristics, SBP1 and GPX1. Nineteen samples surgically removed from patients with HCC were included in this trial. All samples were preserved in liquid nitrogen immediately after resection and were analyzed within 2 weeks. These 19 samples were divided into 2 groups (N1–N9, V1–V10) based on their tumor characteristics (Supplementary Table S1). **A**, the vascular invasive group (VI group) had consistently low expressions of SBP1 whereas the nonvascular invasive group (NVI group) had higher and varied expressions of SBP1. **B**, GPX1 activity of the VI group was consistently at a relatively high level whereas the NVI group also exhibited a varied and lower activity of GPX1. Samples with high expression of SBP1 had limited GPX1 activity (e.g., N1, N7, and N8) whereas samples with lower expression of SBP1 had relatively high GPX1 activity (e.g., N4, N9, V2, and V8). **C**, the possible relationship among SBP1, GPX1, HIF-1 α , and ROS.



subpopulations. Interestingly, in the subpopulation of patients with HCC within the Milan criteria, Kaplan–Meier survival curves revealed that SBP1 was not an effective prognostic factor for OS ($P > 0.05$) but was for early recurrence ($P = 0.039$; Fig. 6C). However, in the subpopulation of patients with HCC beyond Milan criteria with positive SBP1 expression in tumor tissues, only 35.85% (19 of 53) of patients recurred within 2 years. The results indicated that even patients beyond Milan criteria could experience a relatively longer OS and lower recurrence rate with tumors positive for SBP1 expression ($P < 0.001$). The prognostic significance of SBP1 was retained in the subpopulation of patients with HCC beyond Milan criteria (Fig. 6D).

Discussion

As shown by our study, most HCC cell lines have a minimal SBP1 expression, with the exception of SMMC7721. Compared with other HCC cell lines, SMMC7721 has a low metastatic potential (24). In our study, the migration potential of SMMC7721 cells was inhibited by the expression of SBP1. However, SBP1 only exhibited its impact on cancer cell proliferation and apoptosis following treatment with hydrogen peroxide; these results indicated that SBP1 might exert its tumor suppressive power through modulation of the tumor redox microenvironment.




Figure 6. SBP1 expression in tumor tissue and prognosis. Three hundred and twenty-three HCC samples surgically removed between 2003 and 2004 were included here. A, representative photomicrographs of tumor tissues showing the different staining patterns are presented here and are graded from 0 to +++ . B, Kaplan–Meier survival curves showed that patients with negative expression of SBP1 in tumor cells experienced shorter OS periods ($P < 0.001$) and higher recurrence rates ($P < 0.001$) than patients with positive expression of SBP1. C, Kaplan–Meier survival curves revealed that SBP1 was not a significant prognostic factor for OS in HCC within Milan criteria ($P > 0.05$) but was significant for the recurrence in these patients ($P = 0.039$). D, in the subpopulation of patients with HCC beyond Milan criteria, SBP1 was a significant prognostic factor for OS ($P < 0.001$) and recurrence ($P < 0.001$).

GPX1 is the most important antioxidant enzyme that protects cells from ROS such as hydrogen peroxide and singlet oxygen species (29). ROS have the potential to create oxidative stress within cells that causes DNA damage, pro-

tein degradation, peroxidation of lipids, and finally leads to cell transformation or death based on ROS concentration (30). It is a well-documented fact that cancer cells are under high levels of oxidative stress compared with normal cells

and they require defense against ROS to survive (31). Many studies have already reported that GPX1 may protect cancer cells under conditions of severe oxidative stress as it has been observed that increased GPX1 activity can inhibit apoptosis (14, 15), reduce tumor sensitivity toward ROS-generating anticancer drugs (17, 18), and promote the more malignant stages of cancer (16). Our findings showed that SBP1 could greatly inhibit the activity, but not expression, of GPX1 in cancer cells both *in vitro* and *in vivo*; the translocation of GPX1 to the nucleus in cancer cells under oxidative stress may facilitate the antioxidant functions of GPX1, whereas the formation and combination of GPX1 and SBP1 nuclear bodies might inhibit this process. The formation of this SBP1-GPX1 complex has also been validated by coimmunoprecipitation in a prior study, which suggested that this phenomenon was a direct physical interaction (19). We also noticed the expression level of SBP1 was upregulated by oxidative stress (Fig. 2C). Normally, the high level of oxidative stress in cancer cells (usually caused by tumor microenvironment or drug-induced ROS) would lead to cellular apoptosis rather than survival or transformation due to the inhibition of GPX1 activity by the upregulated SBP1. However, as the expression of SBP1 in HCC and many other cancers was reduced (mechanisms might include DNA methylation and chromatin remodeling; ref. 32), the intensive oxidative stress in the tumor microenvironment could be attenuated by the activation of GPX1, leading to cancer cell survival, proliferation, malignant transformation, and even metastasis (31).

We observed a relationship among SBP1, HIF-1 α , and ROS. ROS could initiate the activation of HIF-1 α (21), whereas HIF-1 α could regulate the expression of SBP1 through a hypoxia response element in its promoter region (20). On the basis of this effect, ROS would elevate the expression of SBP1 through HIF-1 α mediation. This was supported by our Western blotting results as showed in Fig. 2C. However, we further observed that the SBP1-silenced cancer cells had a diminished HIF-1 α expression under oxidative stress, which indicated that SBP1 could somehow counter-regulate the expression of HIF-1 α during cellular oxidative stress (Fig. 2C). A possible explanation for this phenomenon was that the exogenous ROS in SBP1-silenced cells was immediately degraded by GPX1, leading to diminished HIF-1 α expression. It has been reported that HIF-1 α can suppress the epithelial-mesenchymal transition through the p53 pathway (also, ROS is a well-known initiator of p53-mediated apoptosis; ref. 33) and inhibit malignant tumor conversion (20, 34, 35). This might also be the reason for the increased malignancy and invasive characteristics of tumors with low SBP1 expression. We illustrated the possible relationship of SBP1, GPX1, HIF-1 α , and ROS (Fig. 5C).

As most of the anticancer agents kill tumor cells by generating ROS or amplifying oxidative stress (31, 36, 37), we concluded that increased SBP1 expression and decreased GPX1 activity could elevate tumor chemosensitivity. This conclusion was supported by several previous studies, which investigated SBP1 and GPX1 separately

(8, 18, 38). On the other hand, the poor responses of patients with HCC to chemotherapy might be due to low SBP1 expression and high GPX1 activity, thus increasing SBP1 expression and decreasing GPX1 activity could be a novel strategy for cancer treatment. However, SBP1 and GPX1 are both selenium-containing proteins, and attempts to reduce cancer risk by simple selenium supplementation in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) have already failed (39). However, recent studies have found certain forms of selenium (such as SeL) can act as pro-oxidants rather than antioxidants and have chemotherapeutic potential by inducing cancer cell apoptosis while leaving normal cells unaffected (40, 41). These certain forms of selenium might exclusively elevate the level of SBP1 rather than GPX1, which might provide a new tool in cancer treatment but requires further investigation.

Our clinical data validated the possible role of SBP1 in cancer biology. Patients with positive SBP1 expression experienced longer periods of OS and lower recurrence rates, indicating that negative SBP1 expression could be a potential biomarker predicting early recurrence/poor prognosis and guide our follow-up treatment in patients with HCC after surgery. When we further stratified patients by Milan criteria, which are widely accepted guidelines for early stage liver transplantation, the survival curves in this study show that negative SBP1 expression in the tumor cells correlated with higher early recurrence rates in patients within the Milan criteria. However, no significant difference was observed with regard to survival periods, thus the predictive significance of SBP1 in this subpopulation would help clinicians identify patients at high risk of early recurrence and enable them to administer rational adjuvant therapy after resection or liver transplantation. However, we noticed that SBP1 is a more effective predictor for patients with HCC beyond the Milan criteria rather than for those within the Milan criteria (Fig. 6C and D). This could be understood by the role of SBP1 in the tumor redox microenvironment considering that patients in the advanced stages of cancer often suffer from more severe hypoxia and oxidative stress than those in the early stages. On the basis of this conclusion, treatment of patients beyond the Milan criteria with SBP1 positive expression should be more aggressive, for these patients can also achieve excellent survival outcomes. Furthermore, the use of glutathione treatment in patients with cancer, especially advanced-stage cancers, should be completed with caution, for glutathione may elevate the activity of GPX1 and promote tumor development based on our findings and those of other groups (42). Taken together, our data indicate that SBP1 is a tumor biomarker with prognostic value in patients with HCC. Determination of SBP1 expression may be useful for personalized therapeutic strategies and decisions about individuals outside of the Milan criteria who could benefit from more aggressive treatment, such as liver transplantation. Currently, the outcomes of these patients are very difficult to predict using conventional clinical indices.

In conclusion, decreased expression of SBP1 could lead to higher GPX1 activity and a diminished HIF-1 α expression in

Huang et al.

HCC; thus, SBP1 might exert its tumor suppressive function as a regulator of the tumor redox microenvironment. SBP1 could be a novel biomarker for predicting prognosis and guiding personalized therapeutic strategies, especially in patients with advanced HCC.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: C. Huang, G. Ding, C. Gu, T. Kondo, J. Fan
Development of methodology: C. Huang, G. Ding, Y. Ji, T. Kondo
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C. Huang, C. Gu, J. Zhou, Y. He, T. Kondo, J. Fan
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C. Huang, G. Ding, C. Gu, J. Zhou, M. Kuang, Y. Ji, Y. He, T. Kondo, J. Fan

Writing, review, and/or revision of the manuscript: C. Huang, G. Ding, C. Gu, J. Zhou, M. Kuang, T. Kondo, J. Fan

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): C. Huang, C. Gu, J. Zhou, T. Kondo, J. Fan

Study supervision: C. Huang, C. Gu, T. Kondo, J. Fan

Grant Support

The study was supported by grants from the National Natural Science Foundation of China (NSFC; no. 30600605), the Major Program of NSFC (no. 81030038), and the National Key Sci-Tech Project of China (2008ZX10002-019).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 20, 2012; revised March 2, 2012; accepted March 18, 2012; published OnlineFirst April 18, 2012.

References

- Rayman MP. The importance of selenium to human health. *Lancet* 2000;356:233-41.
- Chang PW, Tsui SK, Liew C, Lee CC, Waye MM, Fung KP. Isolation, characterization, and chromosomal mapping of a novel cDNA clone encoding human selenium binding protein. *J Cell Biochem* 1997;64:217-24.
- Whanger PD. Selenium and its relationship to cancer: an update. *Br J Nutr* 2004;91:11-28.
- Papp LV, Holmgren A, Khanna KK. Selenium and selenoproteins in health and disease. *Antioxid Redox Signal* 2010;12:793-5.
- Kryukov GV, Gladyshev VN. Mammalian selenoprotein gene signature: identification and functional analysis of selenoprotein genes using bioinformatics methods. *Methods Enzymol* 2002;347:84-100.
- Brigelius-Flohe R. Selenium compounds and selenoproteins in cancer. *Chem Biodivers* 2008;5:389-95.
- Li T, Yang W, Li M, Byun DS, Tong C, Nasser S, et al. Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. *Mol Nutr Food Res* 2008;52:1289-99.
- Silvers AL, Lin L, Bass AJ, Chen G, Wang Z, Thomas DG, et al. Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity. *Clin Cancer Res* 2010;16:2009-21.
- Kim H, Kang HJ, You KT, Kim SH, Lee KY, Kim TI, et al. Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. *Proteomics* 2006;6:3466-76.
- Chen G, Wang H, Miller CT, Thomas DG, Gharib TG, Misek DE, et al. Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. *J Pathol* 2004;202:321-9.
- Huang KC, Park DC, Ng SK, Lee JY, Ni X, Ng WC, et al. Selenium binding protein 1 in ovarian cancer. *Int J Cancer* 2006;118:2433-40.
- He QY, Cheung YH, Leung SY, Yuen ST, Chu KM, Chiu JF. Diverse proteomic alterations in gastric adenocarcinoma. *Proteomics* 2004;4:3276-87.
- Corona G, De Lorenzo E, Elia C, Simula MP, Avellini C, Baccarani U, et al. Differential proteomic analysis of hepatocellular carcinoma. *Int J Oncol* 2010;36:93-9.
- Faucher K, Rabinovitch-Chable H, Cook-Moreau J, Barriere G, Sturtz F, Rigaud M. Overexpression of human GPX1 modifies Bax to Bcl-2 apoptotic ratio in human endothelial cells. *Mol Cell Biochem* 2005;277:81-7.
- de Haan JB, Bladier C, Griffiths P, Kelner M, O'Shea RD, Cheung NS, et al. Mice with a homozygous null mutation for the most abundant glutathione peroxidase, Gpx1, show increased susceptibility to the oxidative stress-inducing agents paraquat and hydrogen peroxide. *J Biol Chem* 1998;273:22528-36.
- Ho JC, Chan-Yeung M, Ho SP, Mak JC, Ip MS, Ooi GC, et al. Disturbance of systemic antioxidant profile in nonsmall cell lung carcinoma. *Eur Respir J* 2007;29:273-8.
- Lee WP, Lee CL, Lin HC. Glutathione S-transferase and glutathione peroxidase are essential in the early stage of adriamycin resistance before P-glycoprotein overexpression in HOB1 lymphoma cells. *Cancer Chemother Pharmacol* 1996;38:45-51.
- Vibet S, Goupille C, Bougnoux P, Steghens JP, Gore J, Maheo K. Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. *Free Radic Biol Med* 2008;44:1483-91.
- Fang W, Goldberg ML, Pohl NM, Bi X, Tong C, Xiong B, et al. Functional and physical interaction between the selenium-binding protein 1 (SBP1) and the glutathione peroxidase 1 selenoprotein. *Carcinogenesis* 2010;31:1360-6.
- Scortegagna M, Martin RJ, Kladney RD, Neumann RG, Arbeit JM. Hypoxia-inducible factor-1alpha suppresses squamous carcinogenic progression and epithelial-mesenchymal transition. *Cancer Res* 2009;69:2638-46.
- Pouyssegur J, Mechta-Grigoriou F. Redox regulation of the hypoxia-inducible factor. *Biol Chem* 2006;387:1337-46.
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005;55:74-108.
- Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. *Ann Surg Oncol* 2008;15:1008-14.
- Li Y, Tian B, Yang J, Zhao L, Wu X, Ye SL, et al. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive *in vivo* selection and studies on metastatic characteristics. *J Cancer Res Clin Oncol* 2004;130:460-8.
- Cui JF, Liu YK, Zhang LJ, Shen HL, Song HY, Dai Z, et al. Identification of metastasis candidate proteins among HCC cell lines by comparative proteome and biological function analysis of S100A4 in metastasis *in vitro*. *Proteomics* 2006;6:5953-61.
- Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. *J Natl Cancer Inst* 2008;100:698-711.
- Li JC, Yang XR, Sun HX, Xu Y, Zhou J, Qiu SJ, et al. Up-regulation of Kruppel-like factor 8 promotes tumor invasion and indicates poor prognosis for hepatocellular carcinoma. *Gastroenterology* 2010;139:2146-57 e12.
- Flohe L, Gunzler WA. Assays of glutathione peroxidase. *Methods Enzymol* 1984;105:14-21.
- Mates JM, Perez-Gomez C, Nunez de Castro I. Antioxidant enzymes and human diseases. *Clin Biochem* 1999;32:595-603.

30. Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. *Apoptosis* 2000;5:415–8.
31. Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. *Cancer Cell* 2006;10:175–6.
32. Pohl NM, Tong C, Fang W, Bi X, Li T, Yang W. Transcriptional regulation and biological functions of selenium-binding protein 1 in colorectal cancer *in vitro* and in nude mouse xenografts. *PLoS One* 2009;4:e7774.
33. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. *Nature* 1997;389:300–5.
34. Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, et al. Hypoxia-inducible factors HIF-1 α and HIF-2 α in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. *Cancer Res* 2002;62:2493–7.
35. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1 α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. *Nature* 1998;394:485–90.
36. Mizutani H. [Mechanism of DNA damage and apoptosis induced by anticancer drugs through generation of reactive oxygen species]. *Yakugaku Zasshi* 2007;127:1837–42.
37. Sinha BK, Mimnaugh EG. Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. *Free Radic Biol Med* 1990;8:567–81.
38. Cao S, Durrani FA, Rustum YM. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. *Clin Cancer Res* 2004;10:2561–9.
39. Brozmanova J, Manikova D, Vickova V, Chovanec M. Selenium: a double-edged sword for defense and offence in cancer. *Arch Toxicol* 2010;84:919–38.
40. Drake EN. Cancer chemoprevention: selenium as a prooxidant, not an antioxidant. *Med Hypotheses* 2006;67:318–22.
41. Lipinski B. Rationale for the treatment of cancer with sodium selenite. *Med Hypotheses* 2005;64:806–10.
42. Scarbrough PM, Mapuskar KA, Mattson DM, Gius D, Watson WH, Spitz DR. Simultaneous inhibition of glutathione- and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress. *Free Radic Biol Med* 2012;52:436–43.

Quantitative Proteomic Analysis Identified Paraoxonase 1 as a Novel Serum Biomarker for Microvascular Invasion in Hepatocellular Carcinoma

Cheng Huang,^{†,‡} Yuwei Wang,^{†,‡} Shengdong Liu,^{†,‡} Guangyu Ding,^{†,‡} Weiren Liu,[†] Jian Zhou,[†] Ming Kuang,[‡] Yuan Ji,[§] Tadashi Kondo,^{*,||} and Jia Fan^{*,†}

[†]Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School, Fudan University, Key Laboratory for Carcinogenesis & Cancer Invasion, the Chinese Ministry of Education, Shanghai, China

[‡]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China


[§]Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China

^{||}Division of Pharmacoproteomics, National Cancer Center Research Institute, Tokyo, Japan

Supporting Information

ABSTRACT: This study aimed to identify serum biomarkers for microvascular invasion (MVI) in hepatocellular carcinoma (HCC). MVI is a histological sign of micrometastasis in the liver and is considered as one of the most powerful prognostic factors in HCC. The serum of HCC patients with different vascular invasion statuses was examined by iTRAQ-based proteomic profiling. The expression levels of 24 proteins were associated with the extent of vascular invasion in the pooled samples of 45 HCC cases. Western blot analyses in 90 HCC cases confirmed the correlation of the expression level of paraoxonase 1 (PON1) with the extent of vascular invasion. ELISA assays demonstrated the diagnostic utility of the PON1 level, with the area under curve values of 0.847 and 0.889 for the MVI and gross vascular invasion, respectively, relative to the patients without vascular invasion, in a cohort of 387 additional HCC cases. Immunohistochemistry revealed that PON1 expression in tumor cells was inversely correlated with the extent of vascular invasion in 200 additional HCC cases. In conclusion, using a proteomic approach, we found that serum PON1 was a novel diagnostic biomarker for MVI. The prognostic values of serum PON1 and its possible therapeutic applications are worth further investigation.

KEYWORDS: hepatocellular carcinoma, paraoxonase 1, microvascular invasion



INTRODUCTION

Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer death worldwide.¹ Although early diagnosis and surgical treatments have significantly improved overall survival rates, long-term survival rates remain poor because of high recurrence rates and metastasis, even with curative resection and transplantation.^{2,3} Although clinical parameters correlate with prognosis and are used to determine the therapeutic strategies in HCC patients, the prediction of prognosis is far from satisfactory.^{4,5} HCC patients often exhibit different clinical outcomes even when they are diagnosed at the same clinical stage. Therefore, more accurate prognostic modalities have long been desired for patients with HCC.

The presence of vascular invasion is regarded as one of the most important risk factors for poor prognosis because it is significantly associated with intrahepatic recurrence within two years after surgery.^{6,7} Vascular invasion can be classified as gross vascular invasion (GVI) or microvascular invasion (MVI) on the basis of pathological observations, reflecting the degree of

vascular invasion. The status of GVI and MVI represent malignant features of HCC and discrete prognoses for patients.⁸ GVI can be diagnosed preoperatively using a radiological examination. GVI represents a late stage and is a crucial survival risk factor for hepatic resection. In contrast, MVI can currently be detected only by postresection histological examination, which greatly limits the utility of MVI when patients are given nonsurgical treatments, such as radiofrequency ablation, ethanol injection or transcatheter arterial chemoembolization.⁷ Identification of proteins responsible for MVI may lead to novel prognostic modalities and therapeutic strategies.

In this study, we aimed to identify predictive serum proteins for MVI in HCC. Isobaric tags for relative and absolute quantitation (iTRAQ) and two-dimensional liquid chromatography–tandem mass spectrometry (2D LC–MS/MS) were used to examine the serum samples of HCC patients with

Received: December 15, 2012

Published: February 26, 2013



different stages of vascular invasion.^{9,10} We identified paroxonase I (PON1) as a novel biomarker candidate for MVI. The correlation between PON1 and vascular invasion was validated by Western blotting and ELISA. Tissue localization and expression of PON1 were determined by immunohistochemistry. This is the first report concerning the clinical utility of PON1 for MVI in HCC.

MATERIALS AND METHODS

Study Patients and Sample Collection

This study included patients with HCC ($n = 677$) who underwent surgical treatment at the Zhongshan Hospital of Fudan University (Shanghai, China). The diagnosis of liver cancer was made by ultrasonography and dynamic computed tomography (CT) or magnetic resonance imaging (MRI), and the diagnosis of HCC was made by pathological examinations of the resected tissues after surgery. No patients had a biopsy prior to the operation or received preoperative treatments. Blood samples were drawn within one week of CT or MRI diagnosis and prior to surgical treatment.

The patients were classified into three groups based on their vascular invasion status: no vascular invasion (NVI), MVI, and GVI. The diagnosis of vascular invasion was made on the basis of established criteria.^{7,8} The presence of MVI was diagnosed when tumor cells were detected in microvessels on microscopic observations by one pathologist (Y.J.) and one clinician (C.H.). In most cases, the presence or absence of MVI were so obvious that two reviewers had consistent results. Inconsistencies, if any, were resolved by discussion as is the usual procedure for pathologic diagnosis in the hospital. The presence of GVI was diagnosed when tumor thrombi were observed in the first or second branches of the portal veins on postoperative pathologic observations or by preoperative radiological tests, such as CT or MRI.

Serum samples were obtained from 90 patients between 2007 and 2008 (Cohort 1, Supporting Information Table S1) for proteomic assays and Western blotting. Those included 30 patients with NVI, 30 with MVI, and 30 with GVI. Another 387 serum samples from 147 patients with NVI, 196 with MVI, and 42 with GVI between 2010 and 2011 (Cohort 2, Supporting Information Table S2) were subjected to validation study by ELISA. Formalin-fixed paraffin-embedded tissue samples were obtained from a separate set of 200 patients between 2003 and 2006 (Cohort 3, Supporting Information Table S3) and examined by immunohistochemistry. Those included 77 patients with NVI, 80 with MVI, and 43 with GVI. The Ethics Committee of Fudan University approved this study, and all patients in this study provided written informed consent. The serum and tissue sample preparation procedures are described in the Supporting Information. The overview of the clinical samples and the study design is illustrated in Figure 1.

iTRAQ Coupled with 2D LC-MS/MS Analysis

To create quantitative protein expression profiles, an iTRAQ experiment was performed with 2D LC-MS/MS. Protein samples were digested and labeled with iTRAQ reagents as described previously.¹¹ Briefly, 45 serum samples from Cohort 1 were subjected to the proteomic study (NVI 1–15, MVI 1–15, GVI 1–15, Supporting Information Table S1). Equal volumes of serum from 15 patients with the same vascular invasion characteristics were mixed, and these three pooled samples were used for biomarker discovery (Figure 1). High-abundance plasma proteins, such as albumin, IgG and IgA, were




Figure 1. Overview of the study design for biomarker discovery, validation, and verification.

removed by the Human 14 Multiple Affinity Removal System (Agilent Technologies, Santa Clara, CA, USA), and then the samples were digested with trypsin and labeled with iTRAQ reagents (Applied Biosystems, Foster City, CA, USA). For iTRAQ analysis, peptides from the NVI group, as well as peptides from the MVI group and the GVI group, were labeled with iTRAQ tags 113, 114, and 115 from an 8-plex iTRAQ reagent kit, respectively. The three samples were then mixed, dried in a speed vacuum, and washed twice with 100 μ L of Milli-Q water to remove any residual reagents. The iTRAQ reagent-labeled peptide mixtures were subsequently separated using a polysulfethyl A strong cation exchange column (5 μ m, 300 \AA , 0.5 \times 23 mm; PolyLC Inc., Columbia, MD, USA) and a ZORBAX 300SB-C18 enrichment column (5 μ m, 300 \AA , 0.5 \times 23 mm; Agilent Technologies). The ACQUITY Ultra Performance LC system (Waters, Milford, MA, USA) was coupled with a QSTAR XL mass spectrometer for electrospray analysis (Applied Biosystems/MDS SCIEX), and survey scans between m/z 400–1800 were acquired with up to six precursors selected for MS/MS analysis from m/z 100–2000 using dynamic exclusion. Fragmentation by rolling collision energy was optimized on the basis of the charge state and mass value of the precursor ions present. All measurements were performed in duplicate. Further methodological details are described in the Supporting Information.

Western Blot Analysis

Western blotting was performed to validate the correlation between the serum level of the identified proteins and the status of vascular invasion in HCC patients in Cohort 1 (Figure 1, Supporting Information Table S1). After diluting crude sera (without depleting abundant proteins) 10-fold with Milli-Q water, an equal volume of diluted serum (8 μ L) and 2 μ L of 5 \times loading buffer were loaded in each lane for 10 or 15% SDS-

PAGE. The PageRuler Prestained Protein Ladder (Fermentas, USA) was used as a molecular weight marker. SDS-PAGE gels were run in duplicate to provide a gel for Coomassie blue staining for determining the amount of protein loaded for each sample (Supporting Information Figure S4). As no reliable internal control protein was available for Western blot analysis of the serum samples, a loading control sample was generated by pooling all of the samples from all groups in equal volumes for each gel. The separated proteins were transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). The membranes were blocked with 5% skim milk in TBS-Tween (25 mM Tris, 190 mM NaCl, 0.05% Tween 20, pH 7.5). Membranes were then incubated at 4 °C overnight with primary antibodies, such as those for amyloid A2 (SAA2; 1:1000, Abnova, Neihu District, Taipei City, Taiwan), clusterin isoform 1 (CLU; 1:1000, Abcam, Cambridge, MA, USA), complement factor B (CFB; 1:1000, Abcam), PON1 (1:1000, Abcam) and apolipoprotein A4 (APOA4; 1:1000, Abcam). After washing, the membranes were incubated at 25 °C for 1 h with the appropriate horseradish peroxidase-conjugated secondary antibody, washed, and developed with a chemiluminescence reagent (Thermo Fisher Scientific, Waltham, MA, USA). The signals from the bound antibodies were developed on films using chemiluminescence reagents (Thermo Fisher Scientific, Waltham, MA, USA). The films were then scanned by ImageScanner (Amersham Pharmacia Biotech), and the optical density of each band was measured with Quantity One (Bio-Rad) for semiquantitative analysis. The loading control sample in each gel was used as the standard for quantification.

Five proteins, SAA2, CLU, CFB, PON1, and APOA4, were initially validated in 45 cases (NVI 1–15, MVI 1–15, GVI 1–15, Supporting Information Table S1), and PON1 was further validated in an additional 45 serum samples (NVI 16–30, MVI 16–30, GVI 16–30, Figure 1, Supporting Information Table S1).

Measurement of Serum PON1 by ELISA

To establish the clinical utility of our findings, PON1 expression was examined in HCC patients in Cohort 2 (Figure 1, Supporting Information Table S2) by ELISA. A commercial ELISA kit (R&D Systems, Minneapolis, MN, USA) was used according to the manufacturer's recommendations. Briefly, 96-well microplates were coated with 100 μ L of the monoclonal antibody to PON1 supplied with the ELISA kit (1 μ g/mL) and incubated at 4 °C overnight. Nonspecific reactions were blocked with 1% bovine serum albumin. Patients' sera diluted with 10% neonatal calf serum were incubated for 2 h at 37 °C. Incubation with the detection antibody, biotinylated goat antihuman PON1 (600 ng/mL), was performed for 2 h at 37 °C, followed by the addition of 100 μ L of a 1:200 dilution of streptavidin horseradish peroxidase for 20 min. Color development was achieved with 100 μ L per well of 3,3',5,5'-tetramethylbenzidine and hydrogen peroxide as a substrate, and sulfuric acid (1 mol/L) was added to stop the reaction. The optical density was measured at 450 nm and referenced to 570 nm on a Synergy 2 multimode plate reader (Biotek, Winooski, VT, USA). The concentrations of PON1 were obtained with a four-parameter logistic curve, fit to the standard value and multiplied by the dilution factor. All measurements were performed in duplicate.

Immunohistochemistry Assay

Expression and localization of PON1 in surgically resected tissues were immunohistochemically examined using paraffin-

embedded tissue samples from HCC patients in Cohort 3 (Figure 1, Supporting Information Table S3). Paired 6- μ m sections from the tumors and noncancerous margins (designated as tumor and peri-tumor tissues, respectively) for each patient were placed on the same slide to eliminate any experimental variation between different slide glasses. The antibody for PON1 (1:400, LifeSpan Biosciences Seattle, WA, USA) was used as a primary antibody. The pH of the citrate epitope retrieval buffer was adjusted to 6.0. Immunohistochemistry was performed using the two-step protocol recommended by the manufacturer (Novolink Polymer Detection System; Novocastra, Newcastle, U.K.). Negative control slides were treated in the same way, except that the primary antibody was omitted. Each slide was imaged using a Hitachi HV-C20A CCD camera (Hitachi, Tokyo, Japan) attached to a Leica DMLA light microscope (Leica Microsystems, Wetzlar, Germany).

The expression level of PON1 was scored on the basis of the intensity of staining of the cytoplasm of the cells over the entire section. The intensity of staining was quantified using a semiquantitative scoring system.¹² Briefly, the intensity of each slide was graded using a 4-point weighted score that was delimited as a semiquantitative scale: 1, extremely low; 2, low; 3, medium; and 4, high. Two pathologists (Y.J. and Y.Y.H.), without knowledge of the patient's characteristics, examined each slide independently, and the scores for all cases were compared to check for discrepancies. The final scores were assigned following discussion.

Statistical Analyses

Protein identification and quantification for the iTRAQ experiment was performed with the ProteinPilot software version 3.0 (Applied Biosystems, USA). The Paragon Algorithm in ProteinPilot software was used for peptide identification and isoform-specific quantification. MS/MS spectra were searched against the International Protein Index v3.45 human database (<http://www.ebi.ac.uk/IPI/IPIhelp.html>) with the following settings: trypsin digestion (semitypic peptides allowed), methyl methanethiosulfonate modification of cysteines, iTRAQ 4-plex-labeled peptides, instrument QSTAR XL, *Homo sapiens*, no special factors, default iTRAQ isotope correction settings, quantification, bias correction, background correction, biological modifications and thorough ID parameters selected.

To minimize false-positive results, a strict cutoff for protein identification was applied with the unused ProtScore >1.3, which corresponds to a confidence limit of 95%, and at least two peptides with 95% confidence were considered for protein quantification. The resulting data set was auto-bias-corrected to remove any variations due to unequal mixing when combining different samples. Proteins with more than 1.2-fold or less than 0.8-fold differences between the groups were considered differentially expressed.

The software package SPSS v13.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. Qualitative variables were analyzed using Pearson's chi-squared and Fisher's exact tests, and quantitative variables were analyzed using ANOVA. Receiver operating characteristic (ROC) curve analysis was used to determine the diagnostic ability of the identified proteins associated with MVI versus GVI. All statistical tests were two-sided, and a *P*-value < 0.05 was considered statistically significant.




Figure 2. Relative quantities of 24 differentially expressed proteins by iTRAQ. The ratio for each protein for the no vascular invasion (NVI) group was given a value of 1. The proteins are organized according to the four trends that were observed. Trend 1: a gradual increase in protein levels with increased vascular invasion (serum amyloid A2 isoform a, clusterin isoform 1, and complement factor B). Trend 2: a gradual decrease in protein levels with increased vascular invasion (serum paraoxonase 1 and apolipoprotein A-IV). Trend 3: a decrease and then an increase in protein levels with increased vascular invasion (alpha 2 globin variant, hemoglobin subunit beta, complement component 4A preproprotein, ceruloplasmin, complement C2, Ig kappa chain V-IV region B17, serpin peptidase inhibitor, clade D (heparin cofactor), member 1, and putative uncharacterized protein DKFZp686H17246). Trend 4: an increase in protein levels followed by a decrease in protein levels with increased vascular invasion (histidine-rich glycoprotein, apolipoprotein C-III variant 1, vitamin D-binding protein, insulin-like growth factor-binding protein complex acid labile chain, antithrombin III variant, complement C7 protein, isoform 1 of complement factor H, complement C1r subcomponent, C4b-binding protein alpha chain, SERPINF2 protein, and isoform 2 of *N*-acetylmuramoyl-L-alanine amidase).

RESULTS

Quantification and Identification of Serum Proteins

Using iTRAQ and 2D LC-MS/MS, we compared the three pooled samples: serum samples from the patients with NVI, those with MVI, and those with GVI (Figure 1). We obtained quantitative data on 409 unique peptides and 73 proteins using iTRAQ and 2D LC-MS/MS (Supporting Information Tables S4, S5). Relative fold changes in concentration were calculated from the ratios of the iTRAQ reporter ion intensities in comparison between NVI and MVI, and between NVI and GVI. We found that 32 proteins showed differential expression in these two comparisons, with iTRAQ reporter ion intensities >1.2 or <0.8 . The 32 proteins included 8 high-abundance proteins (isoform 1 of serum albumin, haptoglobin, IGHA1 protein, alpha-1-acid glycoprotein 1, alpha-1-acid glycoprotein 2, isoform 1 of the fibrinogen alpha chain, IGHM protein, and complement C3) that were supposed to be depleted by the immunodepletion column. As this could reflect the incomplete depletion, we excluded these 8 proteins from the following analysis. Compared with the serum samples that were pooled from patients with NVI, the levels of 11 proteins (vitamin D-binding protein, antithrombin III variant, histidine-rich glycoprotein, insulin-like growth factor-binding protein complex acid labile chain, serum amyloid A2 isoform a, apolipoprotein C-III variant 1, C4b-binding protein alpha chain, SERPINF2 protein, isoform 2 of *N*-acetylmuramoyl-L-alanine amidase, complement C1r subcomponent, and complement C7 protein) were increased, and the levels of 7 proteins (complement component 4A preproprotein, ceruloplasmin, apolipoprotein A-IV, hemoglobin subunit beta, alpha 2 globin variant, complement C2, and putative uncharacterized protein DKFZp686H17246) were decreased in the serum of patients with MVI (Supporting Information Table S6). Compared to those with NVI, in patients with GVI, some proteins

(ceruloplasmin, complement factor B, clusterin isoform 1, serum amyloid A2 isoform a, C4b-binding protein alpha chain, serpin peptidase inhibitor, and Ig kappa chain V-IV region B17) were increased, and the levels of 5 proteins (apolipoprotein A-IV, insulin-like growth factor-binding protein complex acid labile chain, serum paraoxonase 1, apolipoprotein C-III variant 1, and isoform 2 of *N*-acetylmuramoyl-L-alanine amidase) were decreased (Supporting Information Table S6). The levels of serum amyloid A2 isoform a (SAA2), clusterin isoform 1 (CLU), and complement factor B (CFB) were positively correlated with the degree of vascular invasion, and the levels of serum paraoxonase 1 (PON1) and apolipoprotein A-IV (APOA4) were negatively correlated with the degree of vascular invasion (Figure 2, Supporting Information Table S6). We further validated the correlations between the serum levels of these 5 proteins and the vascular invasion status.

Validation of Serum Proteins by Western Blot Analysis

To confirm the correlation between the levels of SAA2, CLU, CFB, PON1, and APOA4 and the status of vascular invasion, 45 serum samples from the iTRAQ study (NVI 1-15, MVI 1-15, GVI 1-15, Supporting Information Table S1) were individually analyzed using Western blots (Supporting Information Figure S1). These experiments were conducted in duplicate, and the gel was stained with Coomassie brilliant blue for loading control analysis (Supporting Information Figure S4). SAA2 was not detected by Western blotting (data not shown). Among the other 4 proteins, only PON1 showed consistent data between the two experiments ($P < 0.05$, Figure 3A). In both iTRAQ and Western blotting, PON1 levels were decreased in MVI and decreased further in GVI, compared with the NVI group. Therefore, an additional 15 serum samples from each patient group (NVI 16-30, MVI 16-30, GVI 16-30, Supporting Information Table S1) were analyzed for PON1 concentration by Western blot (Figure 3B). In these assays, the




Figure 3. Validation of candidate biomarkers by Western blotting. (A) The average relative intensities of the proteins detected by iTRAQ and Western blot assays are normalized to the loading control for comparative studies. The results showed that only PON1 was consistent between two experiments ($P < 0.05$). (B) Serum PON1 level was further examined using Western blotting in 15 additional serum samples from each the patients with NVI (N16–N30), MVI (M16–M30) or GVI (G16–G30). (C) The average concentration of PON1 was 0.74-fold ($P = 0.0633$) and 0.39-fold ($P < 0.0001$) lower in the MVI and GVI groups, respectively, than the NVI group.

average concentration of PON1 was 0.74-fold ($P = 0.06$) and 0.39-fold ($P < 0.0001$) lower in samples of MVI and GVI, respectively, than in serum samples from patients with NVI (Figure 3C). As GVI is a more extended sign of vascular invasion of tumor cells than MVI, PON1 seemed to be responsible for vascular invasion.

Serum PON1 Validation by ELISA

We validated the correlation between PON1 expression and vascular invasion by ELISA in additional 387 HCC cases. Those cases included 147 cases with NVI, 196 cases with MVI and 42 cases with GVI (Cohort 2, Figure 1, Supporting Information Table S2). The mean concentrations of serum PON1 were 449, 158, and 89 pg/mL in the groups of NVI, MVI and GVI, respectively (Figure 4A). The PON1 concentration in the NVI group was significantly higher than in the MVI group ($P < 0.0001$) and GVI group ($P < 0.0001$). These observations were consistent with the data obtained by proteomic studies and Western blotting; the levels of PON1 expression in serum were inversely correlated with the degree of vascular invasion in HCC.

The diagnostic values of serum PON1 were evaluated by ROC curve analysis. The area under the curve (AUC) was 0.847 ($P < 0.001$) and 0.889 ($P < 0.001$) for MVI and GVI, respectively, relative to the patients with NVI (Figure 4B and C).

Immunohistochemical Characteristics

To explore the background of the inverse correlation between the PON1 expression and the vascular invasion, immunohistochemical studies were performed to localize PON1 in tumor and peri-tumor tissues. PON1 localized to the cytoplasm with a variety of staining intensities in HCC cells (Figure 5A). Homogeneous PON1 staining was observed in the cytoplasm of hepatocytes in peri-tumor tissues (Figure 5A). The expression levels of PON1 were evaluated according to a scoring system; representative photomicrographs of tumor and peri-tumor tissues showing the different staining patterns are presented in Figure 5B.

In tumor tissues, the PON1 expression levels were different between NVI, MVI, and GVI; the mean weighted scores were 2.04, 1.82, and 1.65 for the NVI, MVI, and GVI cases,




Figure 4. Validation of the diagnostic value of serum PON1 concentration in predicting vascular invasion by ELISA. (A) The serum PON1 concentration in 387 HCC patients (including 147 NVI, 196 MVI and 42 GVI patients) was determined using ELISA. The mean concentrations of serum PON1 in NVI, MVI, and GVI groups were 449, 158, and 89 pg/mL, respectively. Both MVI and GVI groups showed significantly lower levels of PON1 than the NVI group ($P < 0.0001$). (B) The receiver-operating characteristic curve (ROC curve) for the serum levels of PON1 in patients with GVI compared with patients with NVI. The area under each curve is 0.889 ($P < 0.001$). (C) The ROC curve for serum levels of PON1 in patients with MVI compared with patients with NVI. The area under each curve is 0.847 ($P < 0.001$).

respectively (Table 1). Tumor tissues from the NVI group showed the highest PON1 expression of all three groups ($P < 0.05$).

In peri-tumor tissues, PON1 expression was not different between the three groups: the mean weighted scores were 3.21, 3.24, and 3.23 for the NVI, MVI, and GVI cases, respectively (Table 1).

DISCUSSION

High rates of recurrence and metastasis are the major causes of the poor prognosis of HCC after surgery. Knowing the prognosis allows the best selection of presently available therapies for HCC. However, current clinicopathologic factors, such as histological classification and tumor size, cannot accurately predict the prognosis of HCC patients.^{13–15} Thus, novel modalities to assess the malignant potential of tumor cells and prognostic biomarkers have long been sought.¹⁵ Vascular invasion is a sign of the spread of cancer cells via the vasculature, which may be a key mechanism underlying intrahepatic recurrence and metastasis.^{7,8} Thus, we can consider vascular invasion as an indirect evaluation of prognosis. GVI can be diagnosed preoperatively using radiological examination, and the degree of GVI was highly correlated with a poor prognosis and considered as a prognostic biomarker.¹³ In contrast, the detection of MVI is achieved only by histological observations in resected tissues, and the features of MVI cannot be examined without invasive treatments. As the presence of

MVI is a sign of early metastasis, the detection of MVI before surgery would help select the proper therapeutic modalities.¹⁶ Moreover, the identification of MVI will expand the indications for liver transplantation in HCC. Liver transplantation has long been accepted as a curative treatment option for HCC patients within the Milan criteria, which are based on the number and size of tumors.¹⁷ Recent studies indicated that the criteria could be expanded for patients without vascular invasion; the patients with multiple or larger tumors may achieve acceptable 5-year survival rates.^{5,18} Therefore, by assessing MVI prior to the surgical operation, we will detect more patients who are likely to benefit from liver transplantation. With this background, we aimed to identify serum biomarker candidates to detect MVI.

Comprehensiveness is generally reciprocal to throughput in biomarker studies. Although proteomic modalities enable highly sensitive protein identification in a quantitative manner, it is difficult to examine a large number of samples in a short period. For validation, it is desirable to use a tool that allows parallel examinations of a limited number of molecules, to survey more samples. Moreover, the cost for examinations should be reduced as much as possible, if clinical application is desired. In this study, we initially used three pooled samples for proteomic studies to identify the biomarker candidates using iTRAQ and 2D LC–MS/MS. Then, we achieved candidate validation using a less complex method, Western blotting, for the first screening in 45 samples and for the second screening in another 45 samples. Finally, we examined the clinical




Figure 5. Immunohistochemical staining for PON1 in hepatocellular carcinoma tumors and peri-tumor tissues. (A) PON1 localized to the cytoplasm both in HCC cells and peri-tumor hepatocytes. (B) Tumor cells stained for PON1 in photomicrographs (a), (b), (c) and (d) were scored as 1, 2, 3 and 4, respectively. Peri-tumor hepatocytes in the four representative photomicrographs were all scored as 4. T represents tumor tissue and P represents peri-tumor tissue.

significance of the biomarker candidate by a higher-throughput and less expensive method, ELISA, in an additional 387 cases and evaluated the clinical utilities of the candidates with ROC curve analysis. For verification, we performed immunohistochemistry in the other 200 cases. We initially used a smaller number of samples and a more sophisticated method, and we then examined the results in a larger number of samples and a simpler method. This study design is a role model for biomarker research.

PON1 is a calcium-dependent hydrolase protein synthesized mainly in the liver and secreted into the circulatory system.¹⁹ The systemic immunohistochemical survey of PON1 expression in normal tissues and organs revealed that PON1 was unique to normal hepatocytes and skin (The Human Protein Atlas ver 10.0, <http://www.proteinatlas.org/>). We speculate that serum levels of PON1 might reflect PON1 expression changes in tumor or nontumor tissues during the progression of liver cancer.^{20,21} The immunohistochemical study demonstrated that PON1 expression in tumor tissues inversely is correlated with vascular invasion status, whereas its

expression in peri-tumor tissues shows no significant association (Table 1). This finding suggests that the serum concentration of PON1 may be modulated primarily by PON1 expression in the tumor tissue rather than nontumoral hepatic tissues. These observations are consistent with a previous report, where 35 gene signatures for MVI and GVI were identified; the mRNA level of PON1 was elevated in tumors with NVI compared to tumors with MVI or GVI.²² While there were suggestive observations to correlate the PON1 levels in tissues and serum, further investigation on the functional significances of aberrant regulation of PON1 in tissue and serum should be required before clinical applications.

Serum PON1 has been implicated in cell damage and chronic inflammation in the liver. In chronic liver disease, PON1 levels in serum and hepatic tissue correlate with the degree of liver damage.^{23,24} As an important antiatherosclerotic factor, PON1 has the capacity to prevent oxidation of low-density lipoprotein (LDL), maintain the normal function of endothelial cells, inhibit the adhesion of leukocytes (especially monocytes and macrophages), and reduce chronic inflammation of the vascular wall.^{19,25–27} Because chronic inflammation and leukocyte adhesion are the hallmarks of tumor vascularization and abnormalities in tumor vessels play a crucial role in the process of tumor invasion and metastasis,^{28,29} the anti-inflammatory and vessel normalization roles of PON1 could underlie the inverse correlation between serum PON1 concentration and HCC vascular invasion. The molecular mechanisms underlying the down-regulation of PON1 in HCC with vascular invasion are worth further investigation.

Clinical applications of serum PON1 may require additional investigation. First, our results were obtained only from HBV-induced HCC; therefore, the HCC patients with other etiologies, such as chronic HCV-infection and nonviral diseases, should be included in the further validation studies. Allelic heterogeneity for PON1 in the human population has recently been reported in studies of cardiovascular disease and metabolic syndrome.^{30–32} It is worth investigating whether genotype differences of PON1 exist in HCC patients and whether these differences correlate with tumor invasion and metastasis. Second, the optimal cutoff value should be determined in a larger number of serum samples. Any single marker may not be sufficient for the final decision about therapeutic strategy, and all clinical and pathological information should be considered when using biomarker data. We intend to continue performing a multicenter validation study. Third, the expression of PON1 was reported in many types of cancers such as lung cancer,³³ breast cancer,³⁴ colorectal cancer,³⁵ ovarian cancer,³⁶ endometrial cancer,³⁷ gastric cancer,³⁸ and pancreatic cancer.³⁹ In these cancers, the vascular invasions are observed in the

Table 1. Weighted Scores for the Immunohistochemical Staining of PON1 in HCC Tumor and Peri-tumor Tissues

tissue localization ^a	vascular invasion status ^a	number (%) of patients of different weighted score				mean weighted score ^b	P-value ^c
		1	2	3	4		
T	NVI (N = 77)	18 (23.4)	40 (51.9)	17 (22.1)	2 (2.6)	2.04 ± 0.08	0.031
	MVI (N = 80)	34 (42.5)	28 (35.0)	16 (20.0)	2 (2.5)	1.82 ± 0.09	
	GVI (N = 43)	22 (51.2)	15 (34.9)	5 (11.6)	1 (2.3)	1.65 ± 0.12	
P	NVI (N = 77)	0 (0.0)	3 (3.9)	55 (71.4)	19 (24.7)	3.21 ± 0.06	0.929
	MVI (N = 80)	0 (0.0)	3 (3.8)	55 (68.7)	22 (27.5)	3.24 ± 0.06	
	GVI (N = 43)	0 (0.0)	2 (4.7)	29 (67.4)	12 (27.9)	3.23 ± 0.08	

^aAbbreviations: T, hepatic tumor cells; P, peri-tumor hepatocytes; NVI, no vascular invasion; MVI, microvascular invasion; GVI, gross vascular invasion. ^bValues are given as means ± SEM. ^cP-value < 0.05 was considered statistically significant. P-values were calculated using the ANOVA test.

patients at the developed clinical stage. Therefore, PON1 may generally contribute to the vascular invasion of tumor cells. This hypothesis seems to be attractive, and further expression study on PON1 should be performed in the different types of malignancies.

Our present study has a technical limitation in terms of the coverage of proteome by iTRAQ. The number of serum proteins could be increased by extensive fractionations by affinity columns, size exclusion columns and ion exchange columns, and by the use of mass spectrometry-based, antibody-based or gel-based applications with higher sensitivity. We do not consider that PON1 is the only and best biomarker protein for MVI. Our study clearly demonstrated the presence of biomarker proteins such as PON1 for MVI, and the additional biomarker candidates should be further investigated using the other proteomics modalities.

In conclusion, taking advantage of proteomic modalities and considering global and focused experiments, we identified serum PON1 concentration as a novel preoperative biomarker for MVI in HCC. Serum PON1 concentration can be potentially included in the patient selection standards for more intense follow-up, adjuvant treatment or liver transplantation. Further investigation of the origin of serum PON1 and the mechanisms underlying the inverse correlation between serum PON1 and vascular invasion will allow deep insights into HCC biology.

■ ASSOCIATED CONTENT

⑤ Supporting Information

Supporting tables and figures. Table S1: Clinical and Demographic Characteristics of 90 HCC Patients in Cohort 1. Table S2: Clinical and Demographic Characteristics of 387 HCC Patients in Cohort 2. Table S3: Clinical and Demographic Characteristics of 200 HCC Patients in Cohort 3. Table S4: List of 409 Peptides Identified in HCC Serum Samples by iTRAQ. Table S5: List of 73 Proteins Identified in HCC Serum Samples by iTRAQ. Table S6: Differentially Expressed Proteins Identified in HCC Serum Samples by iTRAQ. Figure S1: Forty five serum samples from the iTRAQ study were further analyzed using Western blot. Figure S2: SDS-PAGE was used to evaluate the immunodepletion of samples by Affinity Removal System Columns. Figure S3: Sequence identification and quantification of representative iTRAQ-labeled peptides of complement factor B, serum paraoxonase 1, clusterin isoform 1, and apolipoprotein A-IV. Figure S4: Coomassie brilliant blue was used to stain the SDS-PAGE gels prior to transfer of the proteins to membranes for Western blot assays. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Tel: 0086-21-64037181 (J.F.). Fax: 0086-21-64037181 (J.F.). E-mail: fan.jia@zs-hospital.sh.cn (J.F.); proteomebioinformatics@gmail.com (T.K.).

Author Contributions

#C. Huang, Y. Wang, S. Liu, and G. Ding contributed equally to this work.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank the patients and clinicians at the Liver Cancer Institute and Zhongshan Hospital, Fudan University, for their contributions to this study. This work is financially supported by grants from the National Natural Science Foundation of China (No. 30600605), the Major Program of NSFC (No. 81030038), and the National Key Sci-Tech Project of China (2008ZX10002-019).

■ ABBREVIATIONS


HCC, hepatocellular carcinoma; MVI, microvascular invasion; GVI, gross vascular invasion; NVI, no vascular invasion; PON1, paraoxonase 1; iTRAQ, isobaric tags for relative and absolute quantitation; 2D LC-MS/MS, two-dimensional liquid chromatography-tandem mass spectrometry; SAA2, amyloid A2; CLU, clusterin isoform 1; CFB, complement factor B; APOA4, apolipoprotein A4; ROC, receiver operating characteristic curve; HBsAg, hepatitis B surface antigen; ALB, albumin; AFP, α -fetoprotein; ALT, alanine transaminase; TB, total bilirubin

■ REFERENCES

- (1) Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. *Ca—Cancer J. Clin.* **2005**, *55* (2), 74–108.
- (2) Poon, R. T. Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. *Ann. Surg. Oncol.* **2009**, *16* (4), 792–4.
- (3) Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. *N. Engl. J. Med.* **2008**, *359* (4), 378–90.
- (4) Dudek, K.; Kornasiewicz, O.; Remiszewski, P.; Kobryn, K.; Ziarkiewicz-Wroblewska, B.; Gornicka, B.; Zieniewicz, K.; Krawczyk, M. Impact of tumor characteristic on the outcome of liver transplantation in patients with hepatocellular carcinoma. *Transplant. Proc.* **2009**, *41* (8), 3135–7.
- (5) Mazzaferro, V.; Llovet, J. M.; Miceli, R.; Bhoori, S.; Schiavo, M.; Mariani, L.; Camerini, T.; Roayaie, S.; Schwartz, M. E.; Grazi, G. L.; Adam, R.; Neuhaus, P.; Salizzoni, M.; Bruix, J.; Forner, A.; De Carlis, L.; Cillo, U.; Burroughs, A. K.; Troisi, R.; Rossi, M.; Gerunda, G. E.; Lerut, J.; Belghiti, J.; Boin, I.; Gugenheim, J.; Rochling, F.; Van Hoek, B.; Majno, P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. *Lancet Oncol.* **2009**, *10* (1), 35–43.
- (6) Bruix, J.; Llovet, J. M. Major achievements in hepatocellular carcinoma. *Lancet* **2009**, *373* (9664), 614–6.
- (7) Roayaie, S.; Blume, I. N.; Thung, S. N.; Guido, M.; Fiel, M. I.; Hiotis, S.; Labow, D. M.; Llovet, J. M.; Schwartz, M. E. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. *Gastroenterology* **2009**, *137* (3), 850–5.
- (8) Lim, K. C.; Chow, P. K.; Allen, J. C.; Chia, G. S.; Lim, M.; Cheow, P. C.; Chung, A. Y.; Ooi, L. L.; Tan, S. B. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. *Ann. Surg.* **2011**, *254* (1), 108–13.
- (9) Gstaiger, M.; Aebersold, R. Applying mass spectrometry-based proteomics to genetics, genomics and network biology. *Nat. Rev. Genet.* **2009**, *10* (9), 617–27.
- (10) Wepf, A.; Glatter, T.; Schmidt, A.; Aebersold, R.; Gstaiger, M. Quantitative interaction proteomics using mass spectrometry. *Nat. Methods* **2009**, *6* (3), 203–5.

- (11) Jin, G. Z.; Li, Y.; Cong, W. M.; Yu, H.; Dong, H.; Shu, H.; Liu, X. H.; Yan, G. Q.; Zhang, L.; Zhang, Y.; Kang, X. N.; Guo, K.; Wang, Z. D.; Yang, P. Y.; Liu, Y. K. iTRAQ-2DLC-ESI-MS/MS based identification of a new set of immunohistochemical biomarkers for classification of dysplastic nodules and small hepatocellular carcinoma. *J. Proteome Res.* **2011**, *10* (8), 3418–28.
- (12) Yiu, G. K.; Chan, W. Y.; Ng, S. W.; Chan, P. S.; Cheung, K. K.; Berkowitz, R. S.; Mok, S. C. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. *Am. J. Pathol.* **2001**, *159* (2), 609–22.
- (13) Qin, L. X.; Tang, Z. Y. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. *J. Cancer Res. Clin. Oncol.* **2004**, *130* (9), 497–513.
- (14) Ye, Q. H.; Qin, L. X.; Forgues, M.; He, P.; Kim, J. W.; Peng, A. C.; Simon, R.; Li, Y.; Robles, A. I.; Chen, Y.; Ma, Z. C.; Wu, Z. Q.; Ye, S. L.; Liu, Y. K.; Tang, Z. Y.; Wang, X. W. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. *Nat. Med.* **2003**, *9* (4), 416–23.
- (15) Villanueva, A.; Hoshida, Y.; Battiston, C.; Tovar, V.; Sia, D.; Alsinet, C.; Cornella, H.; Liberzon, A.; Kobayashi, M.; Kumada, H.; Thung, S. N.; Bruix, J.; Newell, P.; April, C.; Fan, J. B.; Roayaie, S.; Mazzaferro, V.; Schwartz, M. E.; Llovet, J. M. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. *Gastroenterology* **2011**, *140* (5), 1501–12 e2.
- (16) Sumie, S.; Kuromatsu, R.; Okuda, K.; Ando, E.; Takata, A.; Fukushima, N.; Watanabe, Y.; Kojiro, M.; Sata, M. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. *Ann. Surg. Oncol.* **2008**, *15* (5), 1375–82.
- (17) Freeman, R. B., Jr. Transplantation for hepatocellular carcinoma: The Milan criteria and beyond. *Liver Transplant.* **2006**, *12* (11 Suppl 2), S8–13.
- (18) Roayaie, S.; Frischer, J. S.; Emre, S. H.; Fishbein, T. M.; Sheiner, P. A.; Sung, M.; Miller, C. M.; Schwartz, M. E. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. *Ann. Surg.* **2002**, *235* (4), 533–9.
- (19) Precourt, L. P.; Amre, D.; Denis, M. C.; Lavoie, J. C.; Delvin, E.; Seidman, E.; Levy, E. The three-gene paraoxonase family: physiologic roles, actions and regulation. *Atherosclerosis* **2011**, *214* (1), 20–36.
- (20) Ferre, N.; Marsillach, J.; Camps, J.; Mackness, B.; Mackness, M.; Riu, F.; Coll, B.; Tous, M.; Joven, J. Paraonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. *J. Hepatol.* **2006**, *45* (1), 51–9.
- (21) Kedage, V.; Muttigi, M. S.; Shetty, M. S.; Suvarna, R.; Rao, S. S.; Joshi, C.; Prakash, M. Serum paraoxonase 1 activity status in patients with liver disorders. *Saudi J. Gastroenterol.* **2010**, *16* (2), 79–83.
- (22) Minguez, B.; Hoshida, Y.; Villanueva, A.; Toffanin, S.; Cabellos, L.; Thung, S.; Mandeli, J.; Sia, D.; April, C.; Fan, J. B.; Lachenmayer, A.; Savic, R.; Roayaie, S.; Mazzaferro, V.; Bruix, J.; Schwartz, M.; Friedman, S. L.; Llovet, J. M. Gene-expression signature of vascular invasion in hepatocellular carcinoma. *J. Hepatol.* **2011**, *55* (6), 1325–31.
- (23) Keskin, M.; Dolar, E.; Dirican, M.; Kiyici, M.; Yilmaz, Y.; Gurel, S.; Nak, S. G.; Erdinc, S.; Gulden, M. Baseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: relation with disease severity. *Intern. Med. J.* **2009**, *39* (4), 243–8.
- (24) Marsillach, J.; Camps, J.; Ferre, N.; Beltran, R.; Rull, A.; Mackness, B.; Mackness, M.; Joven, J. Paraonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. *BMC Gastroenterol.* **2009**, *9*, 3.
- (25) Bouman, H. J.; Schomig, E.; van Werkum, J. W.; Velder, J.; Hackeng, C. M.; Hirschhauser, C.; Waldmann, C.; Schmalz, H. G.; ten Berg, J. M.; Taubert, D. Paraonase-1 is a major determinant of clopidogrel efficacy. *Nat. Med.* **2011**, *17* (1), 110–6.
- (26) Wheeler, J. G.; Keavney, B. D.; Watkins, H.; Collins, R.; Danesh, J. Four paraonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. *Lancet* **2004**, *363* (9410), 689–95.
- (27) Zabirnyk, O.; Liu, W.; Khalil, S.; Sharma, A.; Phang, J. M. Oxidized low-density lipoproteins upregulate proline oxidase to initiate ROS-dependent autophagy. *Carcinogenesis* **2010**, *31* (3), 446–54.
- (28) Coussens, L. M.; Werb, Z. Inflammation and cancer. *Nature* **2002**, *420* (6917), 860–7.
- (29) Carmeliet, P.; Jain, R. K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. *Nat. Rev. Drug Discovery* **2011**, *10* (6), 417–27.
- (30) Gupta, N.; Singh, S.; Maturu, V. N.; Sharma, Y. P.; Gill, K. D. Paraonase 1 (PON1) polymorphisms, haplotypes and activity in predicting cad risk in North-West Indian Punjabis. *PLoS One* **2011**, *6* (5), e17805.
- (31) Bhattacharyya, T.; Nicholls, S. J.; Topol, E. J.; Zhang, R.; Yang, X.; Schmitt, D.; Fu, X.; Shao, M.; Brennan, D. M.; Ellis, S. G.; Brennan, M. L.; Allayee, H.; Lusic, A. J.; Hazen, S. L. Relationship of paraonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. *JAMA, J. Am. Med. Assoc.* **2008**, *299* (11), 1265–76.
- (32) Kordi-Tamandani, D. M.; Hashemi, M.; Sharifi, N.; Kaykhaei, M. A.; Torkamanzehi, A. Association between paraonase-1 gene polymorphisms and risk of metabolic syndrome. *Mol. Biol. Rep.* **2012**, *39* (2), 937–43.
- (33) Elkiran, E. T.; Mar, N.; Aygen, B.; Gursu, F.; Karaoglu, A.; Koca, S. Serum paraonase and arylesterase activities in patients with lung cancer in a Turkish population. *BMC Cancer* **2007**, *7*, 48.
- (34) Bobin-Dubigeon, C.; Jaffre, I.; Joalland, M. P.; Classe, J. M.; Campone, M.; Herve, M.; Bard, J. M. Paraonase 1 (PON1) as a marker of short term death in breast cancer recurrence. *Clin. Biochem.* **2012**, *45* (16–17), 1503–5.
- (35) Balci, H.; Genc, H.; Papila, C.; Can, G.; Papila, B.; Yanardag, H.; Uzun, H. Serum lipid hydroperoxide levels and paraonase activity in patients with lung, breast, and colorectal cancer. *J. Clin. Lab. Anal.* **2012**, *26* (3), 155–60.
- (36) Camuzcuoglu, H.; Ario, D. T.; Toy, H.; Kurt, S.; Celik, H.; Erel, O. Serum paraonase and arylesterase activities in patients with epithelial ovarian cancer. *Gynecol. Oncol.* **2009**, *112* (3), 481–5.
- (37) Ario, D. T.; Camuzcuoglu, H.; Toy, H.; Kurt, S.; Celik, H.; Erel, O. Assessment of serum paraonase and arylesterase activity in patients with endometrial cancer. *Eur. J. Gynaecol. Oncol.* **2009**, *30* (6), 679–82.
- (38) Akcay, M. N.; Yilmaz, I.; Polat, M. F.; Akcay, G. Serum paraonase levels in gastric cancer. *Hepatogastroenterology* **2003**, *50* (Suppl 2), cclxxiii–cclxxv.
- (39) Akcay, M. N.; Polat, M. F.; Yilmaz, I.; Akcay, G. Serum paraonase levels in pancreatic cancer. *Hepatogastroenterology* **2003**, *50* (Suppl 2), ccxxv–ccxxvii.

Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.


Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>

Available online at www.sciencedirect.com

SciVerse ScienceDirect

www.elsevier.com/locate/jprot

Proteomic identification of the macrophage-capping protein as a protein contributing to the malignant features of hepatocellular carcinoma[☆]

Kazuya Kimura^a, Hidenori Ojima^b, Daisuke Kubota^a, Marimu Sakumoto^a,
Yukiko Nakamura^{a,c}, Tsuyoshi Tomonaga^c, Tmoo Kosuge^d, Tadashi Kondo^{a,*}

^aDivision of Pharmacoproteomics, National Cancer Center Research Institute, Tokyo, Japan

^bDivision of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan

^cLaboratory of Proteome Research, National Institute of Biomedical Innovation, Tokyo, Japan

^dHepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo, Japan

ARTICLE INFO

Article history:

Received 8 August 2012

Accepted 8 October 2012

Available online 17 October 2012

Keywords:

Hepatocellular carcinoma

Venous invasion

Biomarker

Two-dimensional difference gel electrophoresis

Macrophage-capping protein (CapG)

ABSTRACT

Hepatocellular carcinoma (HCC) is one of the most deadly cancers worldwide. We performed a proteomic study to understand the molecular mechanisms underlying metastasis in HCC. Among the 3491 protein spots observed by two-dimensional difference gel electrophoresis (2D-DIGE), we found that 197 and 88 protein spots had statistically significant differences in intensity between tumor and non-tumor tissues and between the tumors with and without vascular invasion, respectively. Mass spectrometry was used to identify the proteins corresponding to those protein spots. We found that compared to tumor tissues without vascular invasion, those with vascular invasion showed markedly upregulated expression of the macrophage-capping protein (CapG). The association of increased CapG expression with vascular invasion in the tumor tissues was confirmed by western blotting. CapG expression levels were equal for non-tumor tissues and tumor tissues without venous invasion, as assessed by 2D-DIGE and western blotting. Silencing of CapG reduced tumor invasion without affecting the proliferation of the HCC cells. These observations suggested that CapG is involved in the process of metastasis by promoting the invasiveness of tumor cells. It may therefore be worth investigating the clinical usefulness of CapG as a biomarker in risk-stratification therapy and as a therapeutic target in HCC.

© 2012 Elsevier B.V. All rights reserved.

1. Introduction

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is an increasingly prevalent clinical problem worldwide. The prognosis of patients in the late stages of the disease is extremely poor [1]. Although molecular-targeted therapies are in development, they have

not yet been established, and surgery is still the first choice for complete cure. A poor clinical outcome in HCC patients is attributable to the highly vascular nature of HCC tumors, which potentiates the tumor cells to disseminate to other parts of the liver. The presence of vascular invasion, which remarkably reflects the vascular invasiveness of the HCC, reflects intrahepatic metastases, which cause early

[☆] Potential conflict of interest: Nothing to report.

* Corresponding author at: Division of Pharmacoproteomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Tel.: +81 3 3542 2511x3004; fax: +81 3 3547 5298.

E-mail address: takondo@ncc.go.jp (T. Kondo).

1874-3919/\$ – see front matter © 2012 Elsevier B.V. All rights reserved.

<http://dx.doi.org/10.1016/j.jprot.2012.10.004>

recurrences [2,3]. Thus, vascular invasion is one of the major clinically important features of metastatic HCCs, and its molecular background is worth investigating for developing improved therapeutic strategies. Novel therapies to prevent recurrence following surgical resection have been challenged, and the use of anti-cancer reagents to prevent recurrence has been reported, including the mTOR inhibitor [4], sorafenib [5], interferon-alpha [6,7], acyclic retinoids [8], and dimeric beta peptides [9]. By assessing the potential for venous invasiveness of tumor cells, we may be able to optimize the use of anti-recurrence drugs in HCC patients, and more importantly, we will be able to identify novel therapeutic targets.

Much effort has been devoted to molecular studies on the early recurrence of HCCs. Proteomic approaches have identified proteins with unique expression in primary tumor tissues from patients who later experienced recurrence [10]. Proteomic studies on HCCs have identified novel proteins, including the APC-binding protein EB1 [11], which can be used as a predictor for HCC recurrence by immunohistochemical analysis. Extensive global expression studies for vascular invasion have also involved mRNA [12] and micro RNA [13] analyses, and several promising biomarker candidates and therapeutic targets have been identified. The clinical usefulness of identifying gene products is of great interest for clinical application in HCC patients.

In this study, we examined the proteins associated with vascular invasion in the primary tumor tissues of the HCC. Although vascular invasion is one of the predictive biomarkers for early recurrence in HCC, its proteomic backgrounds have not been well examined. Using two-dimensional difference gel electrophoresis (2D-DIGE) and our original large-format electrophoresis apparatus, we examined tumor tissues from patients with different levels of vascular invasion. We identified the macrophage-capping protein (CapG) as an important protein associated with vascular invasion and validated the results by proteomics analysis involving antibodies and *in vitro* studies.

2. Materials and methods

2.1. Clinical samples

This study included 26 primary tumor tissue samples from HCC patients and 19 non-tumor liver tissue samples. The non-tumor tissue samples included 2 liver tissue samples of individuals with hepatitis, 2 liver tissue samples of individuals with liver cirrhosis, and 15 normal liver tissue samples. Tumor tissues were obtained from 12 HCC patients who had vascular invasion and from 14 who did not. The clinicopathological observations for the HCC patients are summarized in Table 1, and the clinicopathological data of the individual HCC patients are available in Supplementary Table 1. Tumor and non-tumor tissues were obtained at the time of surgery. The specimens were snap-frozen in liquid nitrogen and stored at -80°C until use. Clinical staging (TNM system) was determined on the basis of diagnostic imaging criteria. None of these patients received anti-neoplastic therapy before surgery. The patients underwent curative surgery at the National Cancer Center Hospital. This study was approved by the ethics committee of the National Cancer Center, and written informed consent was obtained from all the patients.

Table 1 – Summary of clinico-pathological data of HCC patients.

	All cases (n=26)	Venous invasion		p value
		Positive (n=12)	Negative (n=14)	
Age				0.04453
Median	67.5	57	71	
Virus type				0.00429
HBV	12	9	3	
HCV	12	3	9	
NBNC	2	0	2	
Gender				0.51463
Male	19	8	11	
Female	17	4	3	
Histological grade				0.0014
Well differentiated	5	6	0	
Moderately	15	6	9	
Poorly	6	0	5	
Edmondson grade				0.00016
I	6	0	6	
II	14	6	8	
III	6	6	0	

2.2. Protein extraction

Proteins were extracted from surgically resected tissues as previously described [14]. In brief, the frozen tissues were pulverized in liquid nitrogen using metal beads (Multi-beads shaker; Yasui-kikai, Osaka, Japan). The tissues were then treated with urea lysis buffer (2 M thiourea, 7 M urea, 3% CHAPS and 1% Triton X-100). After centrifugation, the supernatant was recovered as a soluble protein fraction and stored at -80°C until use.

2.3. Two-dimensional difference gel electrophoresis

A protein expression profile was created as previously described [14]. In brief, an internal control sample was prepared by mixing an equal amount of a small portion of all the individual samples. Fifteen micrograms of individual samples and the internal control sample were labeled with the Cy5 and Cy3 fluorescent dyes (CyDye DIGE fluor saturation dyes; GE, Uppsala, Sweden), respectively, according to the manufacturer's instructions. The differently labeled protein samples were mixed together, divided into 3 samples, and separated using two-dimensional gel electrophoresis. First-dimension separation was achieved using an IPG dry strip gel, with an isoelectric focusing range of 4 to 7 (24 cm length), and Multiphor II (GE). Protein samples were applied to the IPG gels using a reswelling method and were separated by isoelectric focusing using the IPG gels. Second-dimension separation was performed using SDS-PAGE overnight with our original large-format gel apparatus [14], with a separation distance of 33 cm and a circulating-water cooling system. After gel electrophoresis, gels sandwiched by low-fluorescent glass plates were scanned using a laser scanner (Typhoon Trio,